Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations

Yixuan Zhang(Nanjing Drum Tower Hospital), Shu Zhang(Nanjing University of Chinese Medicine), Xiaoping Zou(Nanjing Medical University), Qisi Zheng(Nanjing Drum Tower Hospital), Jing Zhao(Hebei Medical University), Haochen Su(Nanjing Drum Tower Hospital), Shanshan Shen(Nanjing Drum Tower Hospital), Yao Fu(Illumina (United States)), Ying Lv(Nanjing Drum Tower Hospital), Jianzhuang Wu(Nanjing University), Kun Wang(Xuzhou Medical College), Lei Wang(Nanjing University), Guifang Xu(Affiliated Hospital of Jiangsu University), Ranran Yu(China Pharmaceutical University), Chao Yan(University of Colorado Denver), Siqi Zhou(Jiangsu University), Hao Wu(Nanjing Drum Tower Hospital)
Oncogene
May 12, 2022
10.1038/s41388-022-02328-4
Cited by 30

Related Papers

Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
|PubMed|1994|485
Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva
|Gynecologic Oncology|1990|430
Exogenous lipids promote the growth of breast cancer cells via CD36
|Oncology Reports|2017|197
Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis
|Nature Communications|2023|191